Home | Welcome to Contract Pharma   
Last Updated Monday, May 20 2013
Print

WuXi PharmaTech 1Q11



Published May 11, 2011
Related Searches: Financial Reports
WuXi PharmaTech

1Q Revenues: $93.6 million (+16%)

1Q Earnings: $18.2 million (+17%)

Comments: Laboratory Services revenues grew 12% and Manufacturing Services were up 35% for the quarter. Manufacturing growth was driven by ramp-up of large-scale commercial manufacturing and increased demand for clinical trial materials. Gross margins in manufacturing rose from 19.9% to 26.7%, while Laboratory Services' gross margins dropped from 41.4% to 39.6% due to higher labor costs, Chinese currency appreciation against the dollar, and depreciation expenses from expansion investments. Exchange rates accounted for $1.2 million of the quarter's earnings.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On